• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A human TNF polypeptide mutant having an amino acid sequence of modified human TNF polypeptide, a DNA having a base sequence encoding the above human TNF polypeptide mutant and a method of producing the above human TNF polypeptide mutant by culturing a host transformed with a vector having inserted therein the above DNA. The above human TNF polypeptide mutant is soluble and has antitumor activity.
    公开号:SU1762761A3
    申请号:SU874202872
    申请日:1987-06-19
    公开日:1992-09-15
    发明作者:Ямагиси Юнити；Кавасима Хитоси；Фурута Рюдзи；Котани Хиротада；Наката Катухиса
    申请人:Дайниппон Фармасьютикал Ко., Лтд (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to the field of medicine and biology and can be used to obtain human tumor necrosis factor (TNF).
    The aim of the invention is to increase the antitumor activity in vivo, with low cytotoxic activity In vitro.
    The method is to construct plasmids pHTP16V. pHTP31T, pHTP32S. pHTP32D. pHTP32H. pHTP36V, PHTP73P. pHTP98N, pHTRUS. pH1-115, pHMU-32. pHTP115H. pHTP115D, pHTP115S. pHTP115G, pHTP115T, pHtP117H, pHTP1311, pHTP143V, they transform the E.coll HB 101 strain and cultivate the strains, followed by isolation and purification of the target product.
    Example 1. Construction of the expression plasmid pHMU-32.
    The cloned cDNA encoding human TNF is isolated by treatment with Pst1 restriction endonucleases using recombinant plasmid pHTNF13, prepared according to the procedure described in European Patent Publication No. 155549.
    The cloned cDNA is further processed with restriction nuclei Ava t and Hind tl to isolate a DNA fragment containing the majority of the human TNFα polypeptide coding region. The isolated DNA fragment is called a TNF-DICK fragment.
    TNF-DNA fragment has a size of about 600 p.
    The TNF-DNA fragment is then treated with the restriction endonuclease of the Hpa II endonuclease and Bgl II to cut it into three DNA fragments. Fragments are highlighted. These DNA fragments are named, respectively, DNA-1 fragment, DNA-2 fragment and DNA-3 fragment.
    Then the DNA-1 and DNA-3 fragments are combined using T4-DNA-diagase with speN3
     S
    blowing chemical synthesized oligodeoxyribonucleostid adapter
    (but)
    The 5-CGGGCCTATGCCCTCC-3 3 -CCGGATACGGG-5 linked DNA fragment is referred to as the NY-DNA fragment. The NY-DNA fragment is sequentially linked to the following two chemically synthesized oligo-deoxyribonucleotide adapters (b) and (c)
    (b) 5 -AACTAGTACGCAAGrTCAGGTAAGGAGGTTATC-3
    3 -TTGATCATGCGTTCAAGTGCATTCCTCCAATAGCTA-5
    (c) 5 -GATTATGTCATCTTCl CGAACC-31
    3 -ATACAGTAGAAGAGCTTGGGGGT-5
    The resulting DNA enzyme is referred to as a peptide coding DNA fragment.
    A DNA fragment (about 380 bp) containing the trp promoter region was isolated from the pCT-1 plasmid by double digestion with Hpa I and Aat I endonucleases. The base sequence of the trp promoter region of the 380 p. about. known. The specified DNA fragment 380 p. bind to a peptide coding DNA fragment as described above. The bound DNA fragment is referred to as a promoter-peptide-encoding DNA fragment.
    Separately, plasmid pBR322 was treated with Ava I and Pvu II endonucleases, and the resulting DNA fragment (3.7 kb in size) was isolated by gel electrophoresis in 0.7% agarose. After filling the area between its sticky ends and blunt ends with E. coli DNA polymerase 1 (Klenow fragment) and four types of deoxyribonucleus and three phosphates (dGTP, dATP, dTTP and dCTP), both ends are linked using T4 DNA DNA ligase to construct a new plasmid, which is designated PBRS6.
    Plasmid pBRS6 was digested with the restriction endonucleases Aat II and Hind III into two DNA fragments. The DNA fragment (about 3.6 ppb in size) was isolated and linked using T4 DNA ligase to the promohorpetide-encoding DNA fragment obtained above to construct the expression plasmid pHNY-32. To produce a TNF-32U polypeptide containing 155 amino acids, and with an amino acid sequence in which the aspartic residue in the 32nd position from the N-terminus is replaced by tyrosine (Tyr).
    2. Receiving TNF-32U
    The expression plasmid pHNY-32 was introduced into E. coli HB101 in the usual way (S. N. Cohen et al., Proc, Natl. Acad. Sci, USA, 69.2110 (1972)).
    Transformant (HB101) pHNY-32) is cultivated at 37 ° C for about a day in LB-broth (composition: 1% tryptone, 0.5% yeast extract, 1% NaCi, pH 7.5). The culture is inoculated with 10 volumes of M9 medium (composition: 1.5% N32HP04-12H20. 0.3% KH2P04. 0.05% NaCI. 0.1%, 2 mg / l of vitamin B1, 0.45% casamic acid, 1 mM Md $ 04, 0.1 mM CaCl2 and 0.4% glycerol) containing ampicillin at a concentration of 25 µg / ml (37 ° C, 1 h).
    Then 3-indole acrylic acid is added to a final concentration of 20 µg / ml. After this, the culture was continued for another 24 hours and the cells were separated by centrifugation. The resulting cells are suspended in 50 mM Tris-IP buffer (pH 8) containing 0.1% lysozyme and 30 mM NaCl, and left for 30 minutes in an ice bath. After repeated treatment of the cell suspension by freezing in a bath with dry ice in ethanol and thawing at 37 ° C, the cell extract is separated by centrifugation.
    The cell extract is dialyzed against 20 mM Tris-HC buffer (pH 7.8) and
    By centrifuging the dialysate, a clarified liquid portion is obtained. The liquid portion was applied to a DEAZ-Separate CL-6B column (pharmacy), pre-equilibrated with 20 mM Tris-HCl buffer (pH 7.8).
    After washing the column with the same buffer in order to remove the non-adsorbed components, the target polypeptide (TNF-32U) is zoned under a linear gradient of NaCl from zero to 0.3 M including
    same buffer. Each fraction was subjected to electrophoresis on a VAT-polyacrylamide gel, and fractions containing a polypeptide with a molecular weight of about 17 kilodaltons were collected and combined. United
    the fractions were dialyzed against 20 mm Tris-HCl buffer (pH 7.8) and again subjected to column chromatography on DE-AE Sepharose CL-6B under the above conditions, but with an elution with a lighter concentration gradient of NaCI.
    The fractions containing the target polypeptide are collected, combined and concentrated by ultrafiltration from Diaflo on UM 10 (Amico) membranes.
    Finally, the concentrate is gel-filtered on a Biogel P-6 (Bio-Rad) column using 5 mM phosphate buffer in a saline solution as eluant to obtain purified TNF-32U (yield 20.8 mg / l).
    The N-terminal amino acid sequence of purified TNF-32U using automatic Edm-n decomposition on an amino acid sequence determination device (Applied Viosystem. Model 470A).
    As a result, it was established that the N-terminal amino acid TNF-32U is a serine residue, i.e. the methionine residue due to the trinslation start codon (ATS) is removed from the purified product.
    Example 2.1. Construction of the expression plasmid PHRE 15.
    The TNF DNA fragment obtained in Example 1 (1) was treated with Pvu II and Tag I endonucleases to cut it into four DNA fragments. Fragments are highlighted.
    These DNA fragments are referred to as respectively DNA fragment 4 DNA fragment 5, DNA fragment b and DNA fragment 7. A fragment of DNA-5 is additionally treated with endonuclease Ddlf and get a DNA fragment referred to as a fragment of DNA-8.
    The DNA-8 fragment is combined with the DN K-4 fragment, and then linked to the following two chemically synthesized oligodeoxyribonucleotide adapters (d) and (e).
    (d) S -TGAGGCCAAGCCCTGGTATGAGCTCAT- 3
    3 - CCGGTTCGGGACCATACTCGA-51 and
    (e) 5 -CTATCTGGGAGGGGTCTTCCAG-3p 3 - GTAGATAGACCCTCCCCAGAAAGGTC-5
    DNA fragment-6 and DNA fragment-7 are additionally bound to the obtained DNA fragment using T4 DNA ligase. The resulting DNA fragment is called the PL-DNA fragment.
    The expression plasmid pHPL-115 is constructed by the procedure of Example 1, but instead of the NV-DNA fragment, the PL-DNA fragment is used.
    2. Getting TNF-1151.
    According to the method of example 1- (2) receive the transformant HB101 (pHPL-115).
    Transsformant (HB101 (pHRY15) is cultured overnight at 30 ° C in LB broth (composition: 1% tryptone. 0.5% yeast extract, 1% NaCl, pH 7.5). The culture is inoculated in 10 volumes of modified M9 medium (1.5% Na2HP04-12H20, 0.3% KH2PO4. 0.05% NaCI. 0.1% MShS, 2 mg / l vitamin B1.05.45% casamic acid, 1 mM MgaSO, 0.1 mM CaCIa and 0.4% glycerol) containing ampicillin in the amount of 25 μg / ml at 37 ° C for 1 h.
    Then 3-indole acrylic acid is added to a final concentration of 20 µg / ml. After this, the cultivation is further continued for 24 hours. The cells are harvested by centrifugation, suspended in 50 mM Tris-HCl buffer (pH 8) containing O 1% lysozyme and 30 mP .l and left in
    ice bath for 30 min. After this, the cell suspension is repeatedly processed by freezing (dry ice-ethanol) and thawing (at 37 ° C), the cell extract
    collected by centrifugation.
    The cell extract is dialyzed in a buffer of 20 mM Tris-HCl (pH 7.8), the dialysate is centrifuged. Yadosadzu liquid was applied to a DE-AZ-Sephrosis CL-6B column, pre-equilibrated with 20 mM Tris-HCl buffer (pH 7.8). After washing the column with the same buffer to remove non-adsorbed components, the desired polypeptide is eluted using
    5 linear gradient of NaCl concentration from O to 0.3 M in the same buffer. Each fraction is subjected to SDS-polyacrylamide gel electrophoresis and fractions containing a polypeptide having a molecular weight
    0 about 17 kilodaltons, collected and combined.
    The combined fraction was dialyzed against 20 mM Tris-HCl buffer (pH 7.8) and then subjected to chromatography again in a DEAE-Sepharose CL-bV column in the manner described, but elution was performed under conditions of a weaker gradient of Nad.
    The fractions containing the target polypeptide are collected, combined and concentrated using a Diaflow apparatus using a UM 10 membrane.
    Finally, the concentrate is subjected to gel filtration on a Bio-Gel P-6 column.
    5 using phosphate buffer-containing saline as eluant to obtain purified FN02-1 t5L
    3. Determination of the amino acid sequence.
    0 Amino acid sequences of purified OHO-115L and its peptide fragment are analyzed using automated Erdman decomposition on a device for determining the sequence of amino acids in proteins.
    The peptide fragment was prepared under the following conditions, 500 µg of purified TNF-115L was incubated with 10 µg of lysyl endo-peptidase in 5 mM Tris-HCl buffer (pH 8),
    0 containing 4 M urea in a total volume of 0.1 ml. After incubation at 35 ° C for 15 hours, the resulting digested peptides are isolated by high performance liquid and chromatography, under conditions of
    5 linear gradient elution from 10% to 50% acetonitrile containing 0.07% trifluoroacetic acid in 0.1% trifluoroacetic acid at a flow rate of 1 ml / min for 60 minutes. Peptide fragments are isolated from each fraction and subjected to IV
    amino acid sequences are analyzed using the automatic Edman decomposition method.
    The amino acid at position 115 from the L-terminus of the TNF-115L is confirmed to be a leucine residue.
    The N-terminal amino acid of the purified TNF-115L is a serine residue, which indicates the removal of the methionine residue due to the translation start codon (ATC).
    Example 6. Obtaining other polypeptide mutants-1 human full name,
    1. Construction of expression plasmids.
    An expression plasmid to produce a 155 amino acid polypeptide and having an amino acid sequence in which the asparagine residue at position 32 is replaced from the N-terminus by another amino acid, for example His, Asp and Ser, is constructed as described in Example 2- {1 ), except that instead of the synthetic adapter (a) one of the following chemically synthesized Oligodeoxyribonucleotide ad hocs is used:
    5 -CGGGCCCACGCCCTCC-3
    3 -CCGGGTGCGGG-5
    (to replace his residue)
    S -CGGGCCGATGCCCTCC-S
    3 -CCGGCTACGGG-5 (for replacement with an Asp residue) or
    5 -CGGGCCAGCGCCCTCC-3
    3 -CCGGTCGCGGG-5
    (to replace with Ser residue).
    These plasmids are designated as respectively: pHTP32H. pHTP32D. pHTP32S.
    2. Preparation of polypeptide mutant human TNF.
    Each of the extrusive plasmids obtained in section 1. was introduced into E.coll HB101 by a conventional method, and the transformant was cultivated according to the method of Example 2- (2).
    The target polypeptide is purified from the cell extract according to the method of example 2- (2).
    Example 7. Obtaining other polypeptide mutants-2 human TNF.
    1. Construction of expression plasmids.
    An expression plasmid for producing a 155 amino acid polypeptide and having an amino acid sequence in which the proline residue at the 115th position from the N-terminus is replaced by another amino acid, for example Ser, Asp and Gly, is constructed according to the procedure of Example 2- (1): except for using one of
    chemically synthesized oligodeoxyribonucleotide adapters below, instead of synthetic adapter (d): 5 -TGAGGCCAAGCCCTGGTATGAGTCCAT-3
    S -CCGGTTCGGGACCATACTCAG-S (to replace the Ser residue) S -TGAGGCCAAGCCCTGGTATGAGGACAT-S1
    S -CCGGTTCGGGACCATACTCCC-S1 (to replace Asp residue) 5 - TGAGGCCAAGCCCTGGTATGAGGGCAT-3
    S -CCGGTTCGGGACCATACTCCC-S (for replacement with Gly residue).
    These plasmids are designated pHTP115S. pHTP115D. pHTP115G1. respectively.
    2. Obtaining polypeptide mutants of human TNF.
    Each of the expression plasmids. obtained in section 1 are introduced into E. coli HB101 in the usual way, and the transformant is cultivated according to the method of example 2- {2).
    The target polypeptide is isolated and purified from the cell extract according to the procedure of Example 2- (2).
    Example 8. Obtaining a polypeptide mutant TNF 117H-human full name. designated TNF-117N,
    1. Construction of expression plasmids.
    An expression plasmid for producing a 155 amino acid polypeptide and having an amino acid sequence corresponding to amino acid sequence No. 1 to No. 155 in Table 1, in which the tyrosine residue in the 117th position is replaced from the N-terminus by another acid, for example His are constructed according to the procedure of Example 2- (1), except for using the chemically synthesized oligodeoxyribonucleotide adapter given below instead of the synthetic adapter (e):
    S -CCATCTGGGAGGGGTCTTCCAGrS 3M3TAGGTAGACCCTCCAGAAGGTC-51 This plasmid is designated PHTR117H.
    2. Preparation of TNF-117N The expression plasmid obtained in section (1) was introduced into E. coli HB101 in the usual way, and the transformant was cultured according to the procedure of Example 2- (2).
    The target polypeptide is isolated and purified from the cell extract essentially as described in Example 2- (2).
    Example 9. Obtaining other human TNF polypeptide mutants.
    According to the procedure of Example 2- (1), expression plasmids were constructed. pHGR1bdl obtain TNF-16U, pHTKSH Lpch name
    31T, HTP36V - for OHO-36V, pHTP73P - for TNF-73P. pHTP98N - for TNF-98H, pHTP103R-for TNF-103R, pHTP115T-for TNF-115N, pHTP115H - for TNF-115H, pHTP1311-for TNF-1311 and trPH1414-for TNF-143U, which was transformed with Escherlchla coli. Transformants are cultured and then the polypeptides are isolated and purified as described in Example 2- (2) with the following results:
    CPHO-16V is a polypeptide with the amino acid sequence of formula (1), in which the 16th Ala is replaced by Val (yield 17.5 mg / l);
    TNF-31T is a polypeptide with the amino acid sequence of formula (1) in which the 31st Ala is replaced by Thr (yield 26.4 mg / l);
    TNF-36U is a polypeptide with the amino acid sequence of formula (1), in which the 36th Ala is replaced by Val (yield 8.9 mg / l):
    TNF-73P is a polypeptide with the amino acid sequence of formula (1), in which 73rd Leu is replaced by Pro (yield 2.1 mg / l);
    TNF-98H polypeptide with the amino acid sequence of the formula (1) in which the 98th Pro is replaced by His (yield 3.2 mg / l);
    TNF-SWR is a polypeptide with an amino acid sequence of formula (1), in which 103rd Thr is replaced by Pro (yield 15.9 mg / l);
    TNF-115T is a polypeptide with the amino acid sequence of formula (1) in which the 115th Pro is replaced by Thr (yield 20.5 mg / l);
    TNF-115H is a polypeptide with the amino acid sequence of formula (1), in which the 115th Pro is replaced by His (yield 23.2 mg / l);
    TNF-1311 is a polypeptide with the amino acid sequence of the formula (1) in which the 131st Ser is replaced by He (yield 17 mg / l);
    TNF-143 is a polypeptide with the amino acid sequence of formula (1). in which the 143rd Ala is replaced by Val (yield 16.5 mg / l).
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    A method for producing a polypeptide with the properties of tumor necrosis factor, involving the construction of recombinant plasmid DNA with a mutation in a gene coding for tumor necrosis factor, transformation of the obtained DNA of Escherichia coli strains, cultivation, isolation and purification of the final product with
    the subsequent determination of the amino acid sequence and the target protein, characterized in that, in order to increase the antitumor activity in vivo, recombinant plasmid DNA pHTP16V, pHTP31T, pHTP32S pHTP32D are constructed with low cytotoxic activity in vitro. pHTP32H. pHMU-32, pHTP36V, pHTP73P, pHTP98P, pHTP103f pHPL-115, pHTP115H, pHTP115D. PHTP115S, pHTP115G, pHTP115T, pHTP117P, pHTP1311 or pHTP143V are transformed with the plasmids of the bacterium Escherchla coll HB101, and the target product is purified by applying a cell lysate to a DEAE-Sepharose column. equilibrated with 20 mM Tris-HCl buffer at pH 7.8, elution was performed using a linear gradient of NaCl concentration from 0 to 0.3 M in the same buffer, then polyacrylamide gels were carried out. the fraction obtained is dialyzed with 20 mM Tris-HCl buffer pH 7.8 and applied to a DEAZ-Sepharose column, and elution is carried out using a weak NaCl gradient, the eluate is concentrated, and the concentrate is purified by gel-filtration using phosphate-containing buffer as of the fused protein, wherein the target protein is characterized by the following amino acid sequence:
    Ser Ser Ser Arg Thr Pro Ser Asp Lys Ar Alag Ala Glu Ala Glu Gly Lea Gin Glu Gly Gly Gly Gly Gly Cyl Gly Gly Gly Cyl Gy Gy Cyl Gy Se Arg Glu Pro Alu Gly Gly Ala Glu Ala Lys Pro Alu Glu Glu Aspiru Ary Alu Glu Alu Glu Asp Aro Arg Pro Asp Tyr Alu Glu Ala Glu Gly lie fie Ala
    with the replacement of the 16th amino acid Ala with Val 31st - -Ala- - Thr 326th Asn Asp, His, Ser or Tug 36th Ala Val 73rd Leu Pro 98th 103rd - -Thr- - Pro 115th - -Pro- - Leu, His, Ser, Gly. Asp or
    117th-n-Tug- -His 131nd -S-Ser- - lie 143-it- -Ala- -Val
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1762761A3|1992-09-15|Method for preparation of polypeptide showing properties of tumor necrosis factor
    EP0205404B1|1992-07-15|Hybrid interferons
    EP0155549B1|1991-03-20|Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
    AU600702B2|1990-08-23|Hybrid interferons
    JP2659530B2|1997-09-30|Production of streptavidin-like polypeptide
    Emori et al.1988|All four repeating domains of the endogenous inhibitor for calcium-dependent protease independently retain inhibitory activity. Expression of the cDNA fragments in Escherichia coli.
    EP0502956B1|1997-04-23|Production of recombinant human interleukin-1 inhibitor
    US5304473A|1994-04-19|A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
    US6072039A|2000-06-06|Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
    KR100316347B1|2002-08-27|Recombinant microorganisms expressing a fusion protein of Escherichia coli enterotoxin II signal peptide and fusion protein of human growth hormone and a method of producing human growth hormone using the same
    IE881597L|1988-11-28|Expression of Human Proapolipoprotein A-I
    JPH09135691A|1997-05-27|Preparation of pregrowth and growth hormone of cattle
    EP0315650B1|1993-03-10|Purification of recombinant interleukin-1
    JPH0650990B2|1994-07-06|Method for producing thrombin inhibitor
    US5055555A|1991-10-08|Purification of G-CSF
    JP3011274B2|2000-02-21|Recombinantly produced 3-des-hydroxy-cystatin C polypeptide or modified product thereof
    JPH0787789B2|1995-09-27|DNA molecule encoding lipocortin and transformed host
    US5047333A|1991-09-10|Method for the preparation of natural human growth hormone in pure form
    KR20010083900A|2001-09-03|METHOD FOR OBTAINING ACTIVE β-NGF
    EP0234592A1|1987-09-02|Plasmid containing DNA fragment coding for human immunoglobulin G Fc region protein and use thereof for production of said protein
    EP0352089B1|1994-02-16|A modified human PSTI
    US5656458A|1997-08-12|Expression and processing of amino terminus acetylated FGF's in yeast
    EP0369316A2|1990-05-23|Recombinant interleukin-2 hybrid proteins
    KR970001565B1|1997-02-11|Encoding dna for phytolacca insularis antiviral protein and its expression microorganism
    CA2002210C|2001-04-24|Expression and processing of authentic fgf's in yeast
    同族专利:
    公开号 | 公开日
    DK312387D0|1987-06-19|
    AU7450887A|1988-01-07|
    HU210118B|1995-02-28|
    KR880000471A|1988-03-26|
    US4990455A|1991-02-05|
    EP0251037A3|1988-12-07|
    DE3750056D1|1994-07-21|
    DE3750056T2|1995-04-06|
    HUT46065A|1988-09-28|
    EP0251037B1|1994-06-15|
    DK312387A|1987-12-21|
    PH26714A|1992-09-15|
    AT107362T|1994-07-15|
    EP0251037A2|1988-01-07|
    AU592196B2|1990-01-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3723249A|1970-02-21|1973-03-27|Ajinomoto Kk|Method of producing l-arginine by microorganism|
    JPH0523750B2|1983-09-24|1993-04-05|Kyowa Hakko Kogyo Kk|
    DE3582183D1|1984-03-06|1991-04-25|Dainippon Pharmaceutical Co|DNS ENCODING THE HUMAN TUMORNIC CROSIS FACTOR AND THE HUMAN TUMORNIC CRISIS FACTOR POLYPEPTIDE.|
    GR851626B|1984-07-05|1985-11-26|Genentech Inc|
    EP0200748B1|1984-10-15|1991-02-06|Cetus Corporation|Human tumor necrosis factor|
    EP0205038A1|1985-05-29|1986-12-17|Suntory Limited|Polypeptide, process for preparing it, microorganism and pharmaceutical use|US5081021A|1986-02-04|1992-01-14|Mizuno Den Ichi|DNA encoding HTNF variants exhibiting enhanced activity|
    DE3716513A1|1987-05-16|1988-11-24|Basf Ag|PROTEINS WITH TNF EFFECT|
    DE3837012A1|1988-01-15|1989-07-27|Knoll Ag|USE OF TNF AND LT IN THE PRODUCTION OF MEDICINAL PRODUCTS|
    JPH0797997B2|1988-04-28|1995-10-25|帝人株式会社|Novel bioactive polypeptide|
    DE3843534A1|1988-12-23|1990-07-12|Basf Ag|NEW TNF POLYPEPTIDES|
    DE3922089A1|1989-05-09|1990-12-13|Basf Ag|NEW PROTEINS AND THEIR PRODUCTION|
    US6262239B1|1989-05-18|2001-07-17|Yeda Research And Development Co., Ltd.|TNF receptor-specific antibodies|
    US6232446B1|1989-05-18|2001-05-15|Yeda Research And Development Co. Ltd.|TNF ligands|
    AT212672T|1989-10-24|2002-02-15|Chiron Corp|SYSTEM FOR RELEASING INFECTIOUS PROTEINS|
    US5888814A|1994-06-06|1999-03-30|Chiron Corporation|Recombinant host cells encoding TNF proteins|
    US5519119A|1990-09-21|1996-05-21|Ishihara Sangyo Kaisha Ltd.|Muteins of TNF pharmaceutical compositions and a method of making|
    US5653974A|1990-10-18|1997-08-05|Board Of Regents,The University Of Texas System|Preparation and characterization of liposomal formulations of tumor necrosis factor|
    CA2055168A1|1990-11-21|1992-05-22|Walter Fiers|Tnf-muteins|
    KR970005042B1|1993-02-09|1997-04-11|한일합성섬유공업 주식회사|Tumor necrosis factor-alpha muteine|
    CA2119089A1|1993-03-29|1994-09-30|David Banner|Tumor necrosis factor muteins|
    US6184344B1|1995-05-04|2001-02-06|The Scripps Research Institute|Synthesis of proteins by native chemical ligation|
    US7070771B1|1996-12-09|2006-07-04|Regents Of The University Of California|Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells|
    EE9900461A|1997-04-15|2000-06-15|Farmaceutisk Laboratorium Ferring A/S|Modified TNFα molecules, DNA encoding them, and vaccines containing these TNFα molecules and DNA|
    US7662367B2|2000-03-02|2010-02-16|Xencor, Inc.|Pharmaceutical compositions for the treatment of TNF-α related disorders|
    US7101974B2|2000-03-02|2006-09-05|Xencor|TNF-αvariants|
    US20070172449A1|2000-03-02|2007-07-26|Xencor, Inc.|TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS|
    US7244823B2|2000-03-02|2007-07-17|Xencor|TNF-alpha variants proteins for the treatment of TNF-alpha related disorders|
    US7687461B2|2000-03-02|2010-03-30|Xencor, Inc.|Treatment of TNF-α related disorders with TNF-α variant proteins|
    US7446174B2|2001-03-02|2008-11-04|Xencor, Inc.|Protein based TNF-α variants for the treatment of TNF-α related disorders|
    US7056695B2|2000-03-02|2006-06-06|Xencor|TNF-α variants|
    US7786282B2|2001-12-06|2010-08-31|The Regents Of The University Of California|Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain|
    KR100475403B1|2002-05-28|2005-03-15|재단법인서울대학교산학협력재단|Fabricating Method of Copper Film for Semiconductor Interconnection|
    MXPA05005921A|2002-12-02|2005-10-19|Abgenix Inc|Antibodies directed to tumor necrosis factor and uses thereof.|
    EP2953634B1|2013-02-07|2021-05-26|The General Hospital Corporation|Methods for expansion or depletion of t-regulatory cells|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP14557586|1986-06-20|
    [返回顶部]